malarone filmuhúðuð tafla 250/100 mg
glaxosmithkline pharma a/s - atovaquonum inn; proguanilum hýdróklóríð - filmuhúðuð tafla - 250/100 mg
malaseb vet. hársápa 2 % w/v
dechra veterinary products a/s* - chlorhexidinum díglúkónat; miconazolum nítrat - hársápa - 2 % w/v
aqumeldi
proveca pharma limited - enalapril (maleate) - hjartabilun - lyf sem hafa áhrif á renín-angíótensín kerfið - treatment of heart failure.
apoquel
zoetis belgium sa - oclacitinib maleat - umboðsmenn fyrir húðbólgu, að undanskildu barkstera - hundar - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.
enalapril-hydrochlorthiazid krka tafla 20 mg /12,5 mg
krka sverige ab - enalaprilum maleat; hydrochlorothiazidum inn - tafla - 20 mg /12,5 mg
enalapril/hydrochlorothiazide medical valley tafla 20/12,5 mg
medical valley invest ab - enalaprilum maleat - tafla - 20/12,5 mg
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Æxlishemjandi lyf - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
duokopt (joz) augndropar, lausn 20 mg/ml + 5 mg/ml
laboratoires thea s.a.s. - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml + 5 mg/ml
daren tafla 10 mg
teva b.v.* - enalapril maleate - tafla - 10 mg
daren tafla 20 mg
teva b.v.* - enalapril maleate - tafla - 20 mg